Twinrix Alternative Schedule Study
A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20)
To compare the efficiency of protection against hepatitis-B virus by administration of the combined vaccine against hepatitis A and B using the schedule 0-1-12 months against the schedule 0-1-6 months.
- To compare the seroconversion (>= 1 IU/l) and seroprotection (>= 10 IU/l) rate at month 6,7,12 and 13.
- To compare the distribution of anti-HBs at these different moments.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, B-3001
- IDEWE
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older;
- a good physical condition as confirmed by history and physical examination at entry of the study;
- for female participants who could become pregnant in the course of the study a contraceptive programme is foreseen;
- all participants have provided written informed consent.
Exclusion Criteria:
- Employees occupationally exposed to hepatitis B virus
- Other exclusion criteria listed for the vaccine (licensed vaccine):
- Each acute disease at the inclusion in the study;
- A history of hypersensibility to one of the components of the vaccine;
- Simultaneous participation in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Anti-HBs antibodies concentration 1 month after 3th vaccine dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Natural evolution of anti-HBs antibodies concentration between 2nd and 3th vaccine dose (5-11 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Antoon A De Schryver, M.D., PhD, IDEWE Occupational Health Services
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IDEWE-301
- 04-033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.